Onco-Innovations Integrates PNKP Inhibition, Nanoparticle Delivery, and AI to Address Cancer Drug Development Challenges
July 27th, 2026 1:05 PM
By: Newsworthy Staff
Onco-Innovations is advancing its lead candidate ONC010, which combines a novel DNA repair target with nanoparticle delivery and AI-driven trial design, aiming to improve efficacy and patient selection in oncology.
Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is pursuing a strategy that integrates three emerging frontiers in cancer drug development: novel biology targeting DNA repair beyond PARP, advanced nanoparticle drug delivery, and artificial intelligence for clinical trial optimization. The company's approach aims to address persistent challenges in oncology, including tumor resistance, high clinical trial failure rates, and drug toxicity.
Onco-Innovations' lead candidate, ONC010, is a PNKP inhibitor, a target within the DNA Damage Response (DDR) pathway distinct from PARP. By inhibiting PNKP, ONC010 aims to block cancer cells' ability to repair DNA damage caused by radiation or chemotherapy, potentially enhancing the efficacy of these treatments. The company pairs this inhibitor with a nanoparticle delivery system designed to improve drug solubility, stability, and tumor targeting, which may reduce systemic toxicity.
In addition to its biologic and delivery innovations, Onco-Innovations incorporates AI through its Inka Health subsidiary and the SynoGraph causal AI platform. These tools are intended to support patient stratification, clinical trial design, and real-world evidence generation. By using AI to identify biomarkers and predict patient responses, the company hopes to increase the probability of clinical success and accelerate development timelines.
The company is currently advancing ONC010 through IND-enabling studies, manufacturing, and regulatory work. The integration of these three technologies positions Onco-Innovations to potentially overcome some of the most persistent hurdles in oncology drug development. For more information, visit the company's newsroom at ibn.fm/ONNVF.
This press release is disseminated on behalf of Onco-Innovations Limited and may include paid advertising. InvestorWire, a specialized communications platform, is distributing this release. For more information about InvestorWire, visit https://www.InvestorWire.com. See full terms of use and disclaimers at https://www.InvestorWire.com/Disclaimer.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
